Fujifilm establishes Bio CDMO Division for biopharmaceuticals.

The division will comprise Fujifilm Diosynth Biotechnologies USA, Inc., FUJIFILM Diosynth Biotechnologies UK in the UK, and Kalon Biotherapeutics (currently FUJIFILM Diosynth Biotechnologies Texas) acquired in 2014, and strives for combined sales of 100 Bill. Yen in FY 2023.

Fujifilm news release, Feb. 28, 2017

Most popular posts:

This website stores cookies on your computer. These cookies are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to to opt-out of any future tracking, a cookie will be setup in your browser to remember this choice for one year.

Accept or Deny